Given that AD risk genes are enriched in this population (80), mutations in such genes may have an impact on the ability of CD11c+ microglia to cope with Aβ plaque burden, either promoting or limiting AD pathology. The gene discussed is ITGAX; the disease is Alzheimer disease.